by St John's DermAcademy
Our Podcasts are delivered to you by clinicians and academics at St John’s Institute of Dermatology and invited speakers. Our aim is to update you and share practical tips on how experts in their field diagnose and treat common dermatological conditions in our short episodes that you can easily listen to whilst on the go. Our podcasts are targeted at healthcare professionals including dermatology consultants, dermatology trainees, GPs and specialist nurses. Disclaimer: The information on our podcasts is based on the latest evidence and expert opinion at the time of recording. The information is for general purposes only and we cannot offer advice for specific patients. Equally, this information is geared towards healthcare professionals. Any member of the public or patients listening should not use this as advice to treat their own condition or others and should consult their own physician for any medical they may have.
Language
🇺🇲
Publishing Since
5/19/2020
Email Addresses
0 available
Phone Numbers
0 available
July 5, 2024
<p>In this episode our host Dr Sarah Drummond speaks with Professor Catherine Smith and Dr Andrew Pink about eczema therapeutics:<br/><br/>• The use of JAK inhibitors licensed for use in managing eczema including their mechanism of action, monitoring requirements and potential side effects. <br/>• Newer agents currently under investigation. <br/>• The BEACON trial <br/><br/>Recorded: 19 March 2024<br/><br/>For more information, visit: www.stjohnsdermacademy.com/podcasts <br/><br/>Disclaimer: The information on our podcasts is based on the latest evidence and expert opinion at the time of recording. The information is for general purposes only and we cannot offer advice for specific patients. Equally, this information is geared towards healthcare professionals. Any member of the public or patients listening should not use this as advice to treat their own condition or others and should consult their own physician for any medical needs they may have.</p>
July 5, 2024
<p>In this episode our host Dr Sarah Drummond speaks with Professor Catherine Smith and Dr Andrew Pink about eczema therapeutics:<br/><br/>• Where conventional systemic agents fit within the evolving landscape of eczema therapeutics.<br/>• The biologic agents licensed for use in eczema including their mechanism of action, monitoring requirements and potential side effects.<br/><br/>Recorded: 19 March 2024<br/><br/>For more information, visit: www.stjohnsdermacademy.com/podcasts <br/><br/>Disclaimer: The information on our podcasts is based on the latest evidence and expert opinion at the time of recording. The information is for general purposes only and we cannot offer advice for specific patients. Equally, this information is geared towards healthcare professionals. Any member of the public or patients listening should not use this as advice to treat their own condition or others and should consult their own physician for any medical needs they may have.</p>
June 7, 2024
<p>In this episode our host Dr Sarah Drummond speaks with Dr Thomas Tull about bullous pemphigoid:<br/>• The clinical features and risk factors for developing bullous pemphigoid <br/> • How to differentiate bullous pemphigoid from other subepidermal blistering disorders <br/> • Management of bullous pemphigoid including: <br/> o Preferred first and second line agents <br/> o How and when to reduce treatment <br/> o What to do in severe and refractory cases <br/> <br/><b> Resources and further reading:</b> <br/> • European guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology, 2022 (updated) (<a href='https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.18220'>https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.18220</a>) <br/> • British Association of Dermatologists’ guidelines for the management of bullous pemphigoid, 2012 (<a href='https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.12072'>https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.12072</a>)</p><p><b>Disclosure:</b> <br/>Dr. Tull provides consultancy services for Argenx who market Efgartigimod, which has been referenced in Part 1 and 2 of this series. </p><p><b>Recorded date:</b> 26 January 2024<br/><br/>Please visit our website <a href='https://www.stjohnsdermacademy.com/podcasts'>https://www.stjohnsdermacademy.com/podcasts</a> for episode notes and references. </p>
Dr Vanessa Pinder
Elizabeth Day and Sony Music Entertainment
ZOE
The Week Unwrapped
Skin Health Institute
Global
Luke Johnson
JDD Podcast: Ask the Investigator
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.